Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950134-04-002973
Filing Date
2004-03-05
Accepted
2004-03-05 08:05:19
Documents
5
Period of Report
2003-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d13178e10vk.htm 10-K 838248
3 CONSENT OF ERNST & YOUNG LLP d13178exv23w1.htm EX-23.1 1106
4 CONSENT OF ERNST & YOUNG LLP d13178exv23w3.htm EX-23.3 1186
5 CERTIFICATION OF CEO & CFO - RULE 13A-14(A) d13178exv31w1.htm EX-31.1 10545
6 CERTIFICATION OF CEO & CFO - SECTION 906 d13178exv32w1.htm EX-32.1 3960
  Complete submission text file 0000950134-04-002973.txt   857080
Mailing Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701
Business Address 301 CONGRESS AVE SUITE 1850 AUSTIN TX 78701 5127089310
INTROGEN THERAPEUTICS INC (Filer) CIK: 0001018710 (see all company filings)

EIN.: 742704230 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-21291 | Film No.: 04650226
SIC: 2834 Pharmaceutical Preparations